Home Trials Genes Drugs 23andMe Graph Blog Contact

Home
Trials
Genes
Drugs
23andMe
Graph
Blog
Contact

Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

ClinicalTrials.gov
OpenTargets
ClinVar
PubChem

Links

Contact
Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Inotuzumab Ozogamicin - PF-05208773

N/AApproved For MarketingNCT03127605

Pfizer

Overview

Inotuzumab Ozogamicin Expanded Access Program

Study Type

EXPANDED_ACCESS

Interventions

Inotuzumab OzogamicinDRUG

Eligibility

Medical Language ↔ Plain English

Inclusion Criteria: \- Exclusion Criteria: \-

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

NCT03127605 - Inotuzumab Ozogamicin - PF-05208773 | Crick | Crick